Bausch + Lomb flops in ph. 2 with Xiidra and Miebo but advances combo to ph. 3

Bausch + Lomb has come up short in a phase 2 trial, testing its combination of dry eye disease drugs Xiidra and Miebo. | Bausch + Lomb has come up short in a phase 2 trial, testing its combination of dry-eye disease drugs Xiidra and Miebo. While the study missed its primary endpoint, the Ontario eye care specialist has seen enough promise in the combo to advance it to phase 3 development, it said on Tuesday.